Inhibitory effect of pioglitazone on type-2 diabetes induced nuclear damages in wistar rats

International Journal of Pharma and Bio Sciences

Volumn 1, Issue 2, 2010, Pages

  Rabbani, Syed Imam ^a   Devi, Kshama ^a   Khanam, Salma ^a  

^a AL AMEEN COLLEGE OF PHARMACY   (India)

Author keywords

Antioxidant; Bone marrow micronucleus; Nicotinamide; Pioglitazone; Streptozotocin

Indexed keywords

ALPHA TOCOPHEROL; CATALASE; GLUCOSE; INSULIN; PIOGLITAZONE; SUPEROXIDE DISMUTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTI MUTAGENIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD SAMPLING; BONE MARROW CELL; CONTROLLED STUDY; DNA DAMAGE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; GLUCOSE BLOOD LEVEL; IN VIVO STUDY; MALE; MICRONUCLEUS TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT;

EID: 84455202804     PISSN: None     EISSN: 09756299     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. A. Rehman, J. Nourooz-zadeh, W. Moller, H. Tritschler, P. Pereira and B. Halliwell. Increased oxidative damage to all DNA bases in patients with type-II diabetes mellitus. FEBS. Lett 448: 120-122 (1999).
2. J. Blasiak, M. Arabski, R. Krupa, K. Wozniak, M. Zadrozny, J. Kasznicki, M. Zurawska and J. Drzewosk. DNA damage and repair in type 2 diabetes mellitus. Mutat. Res 554: 297-304 (2004).
3. L. Guo and R. Tabrizchi. Peroxisome proliferators-activated receptor gamma as a drug target in the pathogenesis of insulin resistance. Pharmacol. Ther 111: 145-173 (2006).
4. A. Rubenstrunk, R. Hanf, D. W. Hum, J. C. Fruchart and B. Staels. Safety issues and prospects for future generations of PPAR modulators. Biochemica. Biophysica. Acta 177: 1065-1081 (2007).
5. S. A. El-Batron, S. E. Omar, S. M. Nofal and A. R. Baiuomy. Effect of rosiglitazone and nateglinide on serum glucose and lipid profile alone or in combination with the biguanide metformin in diabetic rats. Pharmacol. Res 53: 69-74 (2007).
6. T. Wang, J. Xu, X. Yu, R. Yang and Z. C. Han. Peroxisome proliferators-activated receptor-γ in malignant diseases. Crit. Rev. Oncol. Hematol 58: 1-14 (2006).
7. M. Collino, M. Aragno, R. Mastrocola, M. Gallicchio, A. C. Rosa, C. Dianzani, O. Danni, C. Theimermann and R. Fantozzi. Modulation of the oxidative stress and inflammatory response by PPAR-γ agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur. J. Pharmcol 530: 70- (2006).
8. I. Villegas, A. R. Martin, W. Toma and C. A. de la Lastra. Rosiglitazone, an agoinst of peroxisome proliferators activated receptor gamma, protects against gastric ischemiareperfusion damage in rats: role of oxygen free radicals generation. Eur. J. Pharmacol 505: 195-203 (2004).
9. A. Gumieniczek. Effect of the new thiazolidinediones-pioglitazone on the development of oxidative stress in liver and kidney of diabetic rabbits. Life Sci 74: 553-562 (2003).
10. A. D. Dobrian, S. D. Schriver, A. A. Khraibi and R. L. Prewitt. Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity. Hypertension 43: 48-56 (2004).
11. S. I. Rabbani, K. Devi and S. Khanam. Effect of thiazolidinediones on the erythropoeitic and germinal cells in the male wistar rats. Clin. Med. Oncol 2 423-429 (2008).
12. Y. Yasui, M. Kim and T. Tanaka. PPAR ligands for cancer chemoprevention. PPAR Res 548919 1-10 (2008).
13. P. Masiello, C. Broca, R. Gross, M. Roye, M. Manteghetti and D. Hillaire-Buys. Experimental NIDDM: Development of new model in adult rats administered streptozotocin and nicotinamide. Diabetes 47: 224-229 (1998).
14. H. Ikeda, S. Taketomi, Y. Sugiyama, Y. Shimura, T. Sohda, K. Mequro and T. Fujita. Effect of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arzeimittelforschung 40: 156-162 (1990).
15. A. R. Pathan, B. Viswanad, S. K. Sonkusare and P. Ramarao. Chronic administration of pioglitazone attenuates intracerebroventricular streptozotocin induced-memory impairment in rats. Life Sci 79: 2206-2216 (2006).
16. Y. Ihara, Y. Yamada, S. Toyokuni, K. Miyawaki, N. Ban and T. Adachi T. Antioxidant alpha-tocopherol ameliorates glycemic control of GK rats, a model of type 2 diabetes. FEBS. Lett 473: 24-26 (2000).
17. D. Klein, T. Schubert, R. E. Horch, K. W. Jauch and M. G. Jeschke. Insulin treatment improves hepatic morphology and function through modulation of hepatic signals after severe trauma. Ann Surgery 240: 340-349 (2004).
18. K. K. Vijayalaxmi and R. Venu. In-vivo anticlastogenic effects of L-Ascorbic acid in mice. Mutat. Res 438: 47-51 (1999).
19. A. k. Sinha. Colorimetric assay of Catalase. Anal. Biochem 47: 389-394 (1972).
20. Y. Kono. Generation of superoxide radical during autoxidation of hydroxylamine and an assay for superoxide dismutase. Arch. Biochem. Biophys 189: 189-195 (1978).
21. M. N. Ravishankara, N. Shrivastava, N. Padh and M. Rajani. Evaluation of antioxidant properties of root bark of Hemidesmus indicus R.Br. (Anantmul). Phytomed 9: 153-160 (2002).
22. L. Piconi, L. Quagliaro and A. Ceriello. Oxidative stress in diabetes. Clin. Chem. Lab. Med 41: 1144-1149 (2003).
23. M. Valko, D. Leibfritz, J. Moncol, M. T. D. Cronin, M. Mazur and J. Telser. Free radicals and antioxidant in normal physiological function and human disease. Int. J. Biochem. Cell. Biol. 39: 44-84 (2007).
24. M. Garcia-Ramirez, G. Francisco, F. Garcia-Arumi, C. Hernandez, R. Martinez, A. L. Andreu and R. Simo. Mitochondrial DNA oxidation and manganese superoxide dismutase activity in peripheral blood mononuclear cells from type-2 diabetic patients. Diabetes Metab 34: 117-124 (2008).
25. M. S. Al-Shamsi, A. Amin and E. Adeghate. Beneficial effect of vitamin E on the metabolic parameters of diabetic rats. Mol. Cell. Biochem 261: 35-42 (2004).
26. A. Bedir, Y. Aliyazicioglu, B. Bilgici, Z. Yurdakul, M. Uysal, D. E. Suvaci, A. Okuyucu, H. Kahraman, M. Hokerek and M. Alvar. Assessment of genotoxicity in rats treated with the antidiabetic agent, piogitazone. Env. Mol. Mutagen 49: 185-191 (2008).
27. S. Hans, Y. Zheug and J. Roman. Rosiglitazone, an agonist of PPAR gamma, inhibits non-small cell carcinoma cell proliferation in part through activation of tumor sclerosis complex-2. PPAR Res 29632: 1-8 (2007).